Zacks.com on MSN21h
Lilly's Jaypirca Gets CHMP Nod for 2nd Leukemia Indication in EuropeThe CHMP gives a positive opinion to Eli Lilly's Jaypirca in patients with relapsed or refractory CLL in a post-BTK inhibitor setting.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback